|
KMID : 0378120020290010099
|
|
Chungnam Medical Journal
2002 Volume.29 No. 1 p.99 ~ p.111
|
|
|
Role of Oxymetholone Treatment in Patients with Aplastic Anemia
|
|
Shin Hyun-Young
Kim Seong-Eun
Kwak Seung-Keon
Park Sang-Eun
Park Su-Jin
Yun Hwan-Jung
Jo Deog-Yeon
Kim Sam-Yong
Kwon Kye-Chul
|
|
|
Abstract
|
|
|
|
Response rate to androgen therapy in aplastic anemia has been reported at 20-50%, and patient survival of the treatment group was not different from control group in several randomized trials. We wanted to confirm our hypothesis that the clinical behavior of aplastic anemia in Korea is different from western countries by documenting better response rate and longer survival of aplastic anemia patients who were treated with androgen only. We analyzed retrospectively the data of 51 patients with aplastic anemia who were diagnosed and treated with 100㎎/day of oxymetholone during the period of January 1990 - December 2000. The results are as follows. The sex ratio was 23:28 or 1.21. There were 26 moderate aplastic anemia versus 25 severe aplastic anemia patients. The median age of patients was 42 (18-82) years. 43 (84.3%) patients received oxymetholone as the first-line treatment (Group l), whereas 8 (15.7%) patients received oxymetholone after failure of immunosuppressive therapy (Group 2) Among 43 patients in Group 1, 7 (16%) patients obtained complete response and 16 (37%) patients achieved partial response with an overall response rate of 53%, and among 8 patients in Group 2,1 (13%) patients obtained complete response and 5 (63%) patients partial response with an overall response rate of 75%. There was no significant difference in survival rates between Group 1 and Group 2 (p=0.259). The overall response rate was 57%. Among 29 patients in response group, 21 (72%) patients survived and among 22 patients in Non-response group, 8 (36%) patients survived. There was a significant difference in survival rates between Response group and Non-response group (p=0.020). The overall survival rate was 57%. Kaplan-Meier analysis revealed a longer survival in responders (p=0.0029). The oxymetholone treatment in patients with aplastic anemia increases survival rates and prolongs the survival duration.
|
|
|
KEYWORD
|
|
|
Aplastic anemia, Oxymetholone, Response group, Survival rates, Survival duration
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|